Literature DB >> 31625055

Lipoprotein(a) Change After Sleeve Gastrectomy Is Affected by the Presence of Metabolic Syndrome.

Silvia Paredes1,2, Marta Alves3, Maria Lopes Pereira3, Olinda Marques3, Laura Ribeiro4,5.   

Abstract

BACKGROUND: Patients with metabolic syndrome (MetS) are at high risk of developing cardiovascular disease (CVD) and lipoprotein(a) (Lp(a)) is an independent risk factor for CVD. This study aimed to determine the effect of vertical sleeve gastrectomy (VSG)-induced weight loss on Lp(a) levels in obese individuals.
METHODS: Patients submitted to VSG from January 2011 to July 2015 were included. Anthropometric and metabolic parameters were recorded before and 12 months after surgery. Univariate analysis identified associations between Lp(a) and anthropometry and metabolic parameters, and the logistic regression predictors of Lp(a) decrease after VSG.
RESULTS: MetS was present in 47% of the 330 patients involved. Patients with MetS had higher body mass index (BMI) and triglyceride levels and were more insulin-resistant. No differences were found between groups respecting Lp(a) levels prior to surgery (15.2 mg/dL vs. 15.0 mg/dL, p = 0.795). After surgery, patients without MetS had a decrease in Lp(a) levels (14.7 mg/dL vs. 12.3 mg/dL, p = 0.006), while MetS patients showed no differences (13.9 mg/dL vs. 14.6 mg/dL, p = 0.302). The regression model evidenced that older age and Δ HDL-c were predictors of Lp(a) decrease, whereas the greater the number of MetS components and lower estimated BF% loss, the lesser odds of decreasing Lp(a) after surgery.
CONCLUSIONS: Despite a global improvement of conventional CVD risk factors, only individuals without MetS showed a decrease of Lp(a) levels after VSG. Further studies should explore not only the pathophysiological mechanisms underlying the absence of decrease of Lp(a) levels in MetS patients, but also its impact on the metabolic beneficial changes usually observed after VSG.

Entities:  

Keywords:  Bariatric surgery; Cardiovascular disease; Dyslipidemia; Lipoprotein(a); Metabolic syndrome; Vertical sleeve gastrectomy

Year:  2020        PMID: 31625055     DOI: 10.1007/s11695-019-04212-9

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  49 in total

Review 1.  Lipoprotein(a): A Lipoprotein Whose Time Has Come.

Authors:  Erik Kelly; Linda Hemphill
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-07

2.  Changes in lipoprotein(a) levels and hormonal correlations during a weight reduction program.

Authors:  D N Kiortsis; T Tzotzas; P Giral; E Bruckert; I Beucler; S Valsamides; G Turpin
Journal:  Nutr Metab Cardiovasc Dis       Date:  2001-06       Impact factor: 4.222

3.  Validation of the Friedewald formula for the determination of low-density lipoprotein cholesterol compared with beta-quantification in a large population.

Authors:  André J Tremblay; Hugo Morrissette; Jean-Marc Gagné; Jean Bergeron; Claude Gagné; Patrick Couture
Journal:  Clin Biochem       Date:  2004-09       Impact factor: 3.281

4.  Changes of body composition in patients with BMI 23-50 after tailored one anastomosis gastric bypass (BAGUA): influence of diabetes and metabolic syndrome.

Authors:  M Garciacaballero; A Reyes-Ortiz; M García; J M Martínez-Moreno; J A Toval; A García; A Mínguez; D Osorio; J M Mata; F Miralles
Journal:  Obes Surg       Date:  2014-12       Impact factor: 4.129

Review 5.  Bile acids, obesity, and the metabolic syndrome.

Authors:  Huijuan Ma; Mary Elizabeth Patti
Journal:  Best Pract Res Clin Gastroenterol       Date:  2014-07-11       Impact factor: 3.043

6.  Lipoprotein (a), metabolic syndrome and coronary calcium score in a large occupational cohort.

Authors:  K-C Sung; S H Wild; C D Byrne
Journal:  Nutr Metab Cardiovasc Dis       Date:  2013-06-17       Impact factor: 4.222

7.  FGF19 signaling cascade suppresses APOA gene expression.

Authors:  Indumathi Chennamsetty; Thierry Claudel; Karam M Kostner; Michael Trauner; Gert M Kostner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-01-19       Impact factor: 8.311

8.  Effects of a carbohydrate-restricted diet on emerging plasma markers for cardiovascular disease.

Authors:  Richard J Wood; Jeff S Volek; Steven R Davis; Carly Dell'Ova; Maria Luz Fernandez
Journal:  Nutr Metab (Lond)       Date:  2006-05-04       Impact factor: 4.169

9.  Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium.

Authors:  Christoph Waldeyer; Nataliya Makarova; Tanja Zeller; Renate B Schnabel; Fabian J Brunner; Torben Jørgensen; Allan Linneberg; Teemu Niiranen; Veikko Salomaa; Pekka Jousilahti; John Yarnell; Marco M Ferrario; Giovanni Veronesi; Paolo Brambilla; Stefano G Signorini; Licia Iacoviello; Simona Costanzo; Simona Giampaoli; Luigi Palmieri; Christa Meisinger; Barbara Thorand; Frank Kee; Wolfgang Koenig; Francisco Ojeda; Jukka Kontto; Ulf Landmesser; Kari Kuulasmaa; Stefan Blankenberg
Journal:  Eur Heart J       Date:  2017-08-21       Impact factor: 29.983

10.  Net contribution and predictive ability of the CUN-BAE body fatness index in relation to cardiometabolic conditions.

Authors:  Veronica Davila-Batista; Antonio J Molina; Laura Vilorio-Marqués; Leila Lujan-Barroso; Fernanda de Souza-Teixeira; Rocío Olmedo-Requena; Jorge Arias de la Torre; Lidia García-Martínez; Laura Álvarez-Álvarez; Heinz Freisling; Javier Llorca; Miguel Delgado-Rodríguez; Vicente Martin
Journal:  Eur J Nutr       Date:  2018-06-11       Impact factor: 5.614

View more
  1 in total

Review 1.  The Effect of Bariatric Surgery on Circulating Levels of Lipoprotein (a): A Meta-analysis.

Authors:  Tannaz Jamialahmadi; Željko Reiner; Mona Alidadi; Matthew Kroh; Wael Almahmeed; Massimiliano Ruscica; Cesare Sirtori; Manfredi Rizzo; Raul D Santos; Amirhossein Sahebkar
Journal:  Biomed Res Int       Date:  2022-08-17       Impact factor: 3.246

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.